Related Experiment Video
Updated: Aug 5, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A 20-Year Systematic Review and
Giovanni Leuzzi1, Michele Ferrari1, Federica Sabia1
1Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Oncology Research
|July 25, 2026
Summary
Induction therapy followed by surgery offers good long-term outcomes for advanced Thymic Epithelial Tumors (TETs). However, 10-year survival for these rare cancers has not improved, highlighting the need for new, histology-tailored treatments.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Research
Background:
- Advanced Thymic Epithelial Tumors (TETs), particularly locally advanced thymomas, lack universally accepted management guidelines.
- Multimodal strategies exist, but optimal treatment sequencing for Masaoka-Koga stage III-IVA TETs remains unclear.
- Evaluating induction therapy followed by surgery is crucial for improving outcomes in advanced TETs.
Purpose of the Study:
- To assess the oncological and surgical outcomes of induction therapy (IT) followed by surgical resection in patients with Masaoka-Koga stage III-IVA TETs.
- To conduct a systematic review and meta-analysis of existing literature on IT and surgery for advanced TETs.
- To identify factors influencing survival and response to treatment in this patient population.
Main Methods:
- Systematic review and meta-analysis adhering to PRISMA guidelines, searching PubMed, Embase, and Cochrane Central.
- Inclusion of 24 studies (2003-2023) involving 749 patients treated with IT before surgery.
- Random-effects meta-analysis of Overall Survival (OS) and Progression-Free Survival (PFS), with meta-regression for moderators like histology and treatment period.
Main Results:
- Pooled radiological response rate to IT was 62.8%, with a 71.6% completeness of resection.
- Pooled 5-year OS was 77.6%, 10-year OS was 54.3%, and 5-year PFS was 55.6%.
- Histology significantly impacted 10-year OS and PFS, as did the treatment period on PFS.
Conclusions:
- Induction therapy followed by surgery demonstrates acceptable long-term survival for advanced TETs.
- Histological subtype is a critical prognostic factor in advanced TETs.
- Lack of improvement in 10-year OS over two decades necessitates innovative, histology-specific therapeutic strategies.